Insys Therapeutics, Inc.
INSY
INSY was delisted on the 18th of June, 2019.
116 hedge funds and large institutions have $218M invested in Insys Therapeutics, Inc. in 2017 Q1 according to their latest regulatory filings, with 16 funds opening new positions, 36 increasing their positions, 40 reducing their positions, and 31 closing their positions.
10% less repeat investments, than reductions
Existing positions increased: 36 | Existing positions reduced: 40
16% less funds holding
Funds holding: 138 → 116 (-22)
20% less capital invested
Capital invested by funds: $274M → $218M (-$55.8M)
24% less call options, than puts
Call options by funds: $4.51M | Put options by funds: $5.96M
48% less first-time investments, than exits
New positions opened: 16 | Existing positions closed: 31
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BlackRock
New York
|
+$27.7M |
| 2 |
Norges Bank
Oslo,
Norway
|
+$6.56M |
| 3 |
FCP
Fine Capital Partners
New York
|
+$4.82M |
| 4 |
Thrivent Financial for Lutherans
Minneapolis,
Minnesota
|
+$1.07M |
| 5 |
Point72 Asset Management
Stamford,
Connecticut
|
+$920K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SCM
Scopia Capital Management
New York
|
-$65.6M |
| 2 |
Bank of New York Mellon
New York
|
-$3.43M |
| 3 |
Ameriprise
Minneapolis,
Minnesota
|
-$2.78M |
| 4 |
MC
Maverick Capital
Dallas,
Texas
|
-$2.52M |
| 5 |
FHAM
Folger Hill Asset Management
New York
|
-$2.43M |
INSY Hedge Fund Activity: Q1 2017 in Review
116 of the 4,034 institutional investors tracked by Wall St. Rank reported a position in Insys Therapeutics, Inc. (INSY) for Q1 2017, worth a combined $218M — down 20% from $274M a quarter earlier.
Sellers outnumbered buyers: 31 funds closed out of INSY and 16 opened new positions — a net loss of 15 holders — while 40 trimmed existing stakes and 36 added.
The largest buyer was BlackRock, adding an estimated $27.7M. The largest seller was Scopia Capital Management, exiting entirely with an estimated $65.6M sold.
- 116 institutional investors held Insys Therapeutics, Inc. (INSY) as of Q1 2017, down from 138 in Q4 2016.
- Funds reported $218M of Insys Therapeutics, Inc. stock for Q1 2017, down 20% quarter-over-quarter.
- 16 funds opened new Insys Therapeutics, Inc. positions in Q1 2017 and 31 closed out, a net change of -15 holders.
- The largest Insys Therapeutics, Inc. buyer in Q1 2017 was BlackRock, an estimated $27.7M added.
- The largest Insys Therapeutics, Inc. seller in Q1 2017 was Scopia Capital Management, an estimated $65.6M sold.
Based on aggregated 13F filings for Q1 2017.